deltatrials
Completed PHASE1 INTERVENTIONAL 5-arm NCT04110535

Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users

A Double-blind, Randomized Crossover Study to Assess the Subjective Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users

Sponsor: PRA Health Sciences

Conditions Abuse, Drug
Interventions Midazolam Remimazolam Saline
Updated 4 times since 2019 Last updated: Sep 27, 2019 Started: Jun 23, 2015 Primary completion: Oct 6, 2015 Completion: Oct 6, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Abuse, Drug, this trial is completed. The trial is conducted by PRA Health Sciences and has accumulated 4 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE1

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • PRA Health Sciences
  • Paion UK Ltd.
Data source: Paion UK Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations